<DOC>
	<DOCNO>NCT02480088</DOCNO>
	<brief_summary>Opioid-based intravenous patient-controlled analgesia ( IV-PCA ) offer excellent pain control , however , use inevitably increase incidence postoperative nausea vomiting ( PONV ) . Ramosetron palonosetron commonly use 5-HT3 antagonist prevention treatment PONV . It clear one superior antiemetic efficacy prevention PONV patient use opioid-based IV-PCA . The antiemetic efficacy 5HT3 antagonist may influence polymorphism ABCB1 , drug-transporter gene . This study evaluate relative antiemetic efficacy ramosetron palonosetron patient use IV-PCA spinal surgery impact ABCB1 polymorphism antiemetic efficacy ramosetron palonosetron . The incidence intensity PONV postoperative 48 h assess . ABCB1 polymorphisms 3435C &gt; T 2677G &gt; T/A evaluate patient .</brief_summary>
	<brief_title>Comparison Palonosetron Ramosetron Preventing Patient-controlled Analgesia Related Nausea Vomiting Following Spine Surgery ; Association With ABCB1 Polymorphism</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Patients age 2085 yr undergo spine surgery Taking steroid opioids preoperatively GI motility disorder Uncontrolled diabetes Severe renal hepatic disease Transfer ICU postoperatively Obesity ( BMI &gt; 35 kg/m2 ) Use antiemetic agent within 24 h preoperatively Pregnancy Psychiatric disease Drug alcohol abuser Malignancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>